Insights Into Mutations Induced Conformational Changes and Rearrangement of Fe2+ Ion in pncA Gene of Mycobacterium tuberculosis to Decipher the Mechanism of Resistance to Pyrazinamide
Pyrazinamide (PZA) is the first-line drug commonly used in treating Mycobacterium tuberculosis (Mtb) infections and reduces treatment time by 33%. This prodrug is activated and converted to an active form, Pyrazinoic acid (POA), by Pyrazinamidase (PZase) enzyme. Mtb resistance to PZA is the outcome...
Main Authors: | Asma Sindhoo Nangraj, Abbas Khan, Shaheena Umbreen, Sana Sahar, Maryam Arshad, Saba Younas, Sajjad Ahmad, Shahid Ali, Syed Shujait Ali, Liaqat Ali, Dong-Qing Wei |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-05-01
|
Series: | Frontiers in Molecular Biosciences |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmolb.2021.633365/full |
Similar Items
-
Structural Dynamics Behind Clinical Mutants of PncA-Asp12Ala, Pro54Leu, and His57Pro of Mycobacterium tuberculosis Associated With Pyrazinamide Resistance
by: Aamir Mehmood, et al.
Published: (2019-12-01) -
Gibbs Free Energy Calculation of Mutation in PncA and RpsA Associated With Pyrazinamide Resistance
by: Muhammad Tahir Khan, et al.
Published: (2020-04-01) -
Pyrazinamide resistance in Swedish multidrug-resistant tuberculosis 2003–2013
by: M Mansjö, et al.
Published: (2015-01-01) -
Use of genetic mutations for prediction of resistance to pyrazinamide in M. tuberculosis strains
by: Daniela M Cirillo, et al.
Published: (2015-01-01) -
A comprehensive characterization of PncA polymorphisms that confer resistance to pyrazinamide
by: Adam N. Yadon, et al.
Published: (2017-09-01)